Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-Current Deffered Revenue (2016)

Anika Therapeutics (ANIK) has disclosed Non-Current Deffered Revenue for 7 consecutive years, with $48000.0 as the latest value for Q4 2016.

  • Quarterly Non-Current Deffered Revenue fell 27.27% to $48000.0 in Q4 2016 from the year-ago period, while the trailing twelve-month figure was $48000.0 through Dec 2016, down 27.27% year-over-year, with the annual reading at $48000.0 for FY2016, 27.27% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2016 was $48000.0 at Anika Therapeutics, down from $59000.0 in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $4.3 million in Q1 2012, with the low at $48000.0 in Q4 2016.
  • Average Non-Current Deffered Revenue over 5 years is $1.1 million, with a median of $79940.5 recorded in 2015.
  • The sharpest move saw Non-Current Deffered Revenue plummeted 97.21% in 2014, then skyrocketed 30.74% in 2015.
  • Over 5 years, Non-Current Deffered Revenue stood at $2.2 million in 2012, then dropped by 4.54% to $2.1 million in 2013, then tumbled by 95.04% to $102000.0 in 2014, then tumbled by 35.29% to $66000.0 in 2015, then fell by 27.27% to $48000.0 in 2016.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $48000.0, $59000.0, and $56000.0 for Q4 2016, Q3 2016, and Q2 2016 respectively.